Once-daily emvistegrast posts a clear phase 2 signal in ulcerative colitis
Gilead Sciences has delivered a phase 2 win for emvistegrast, its once-daily oral α4β7 integrin inhibitor in ulcerative colitis. The study’s week 12 data place the drug squarely in the conversation for a crowded inflammatory bowel disease market, with the 200-mg dose outperforming placebo on both clinical response and clinical remission. For a disease defined by relapsing mucosal inflammation, the result matters because α4β7 blockade attacks one of the earliest steps in the inflammatory cascade: immune-cell trafficking into the gut.
At week 12, 66% of patients receiving 200 mg achieved a clinical response, compared with 37% of placebo recipients. Clinical remission followed the same pattern, reaching 31% in the treatment group versus 8% with placebo. Those are not incremental differences at the margins; they suggest a biologically active oral agent capable of suppressing the immune recruitment that drives colonic injury.
The trial is still ongoing, but the first look is enough to sharpen expectations around dose selection and future development. Gilead plans to move into a phase 3 monotherapy study in 2027.
Gut-homing immune cells and why α4β7 blockade can matter
Emvistegrast inhibits α4β7 integrin, a protein on immune cells that helps direct them to the gut. In ulcerative colitis, that trafficking pathway becomes part of the problem: inflammatory cells migrate into intestinal tissue, where they sustain cytokine release, epithelial injury, and the chronic mucosal damage that underlies bleeding, urgency, and diarrhea. Blocking α4β7 does not merely suppress inflammation in a broad, nonspecific way. It interferes with where the inflammation goes.
That mechanism also explains why the oral formulation is strategically important. Current therapies that target the same pathway have already validated the biology, but most require injections or infusion. A once-daily pill introduces a different treatment proposition for patients and clinicians, especially in a disease where long-term adherence often determines whether mucosal healing is sustained or lost between flares.
The Swift trial enrolled 238 adults with moderately to severely active disease and randomized them to three doses of emvistegrast: 25 mg, 75 mg, and 200 mg, alongside placebo. The findings presented at United European Gastroenterology Week 2026 in Barcelona point most strongly to the highest dose. The lower doses were part of the dose-ranging design, but the clearest efficacy readout came from the 200-mg arm.
Mucosal and endoscopic gains extended beyond symptom response
Clinical response alone would not be enough to define success in ulcerative colitis, where symptom improvement can outpace true tissue recovery. The 200-mg dose also improved deeper measures of disease control. Histological endoscopic mucosal improvement reached 25% in the treatment group, compared with 10% on placebo. Endoscopic improvement was reported in 39% of patients receiving emvistegrast, versus 12% of those given placebo.
Those secondary endpoints are clinically meaningful because endoscopy and histology capture the structural and inflammatory burden left behind after symptoms start to improve. A therapy that only dampens stool frequency without healing the mucosa risks leaving the patient vulnerable to relapse, hospitalization, steroid exposure, and eventual escalation to more intensive therapy. In contrast, improvement across both endoscopic and histologic domains suggests that emvistegrast may be doing more than quieting surface symptoms.
A single sentence captures the trial’s most important signal: the highest dose moved both the bedside and the biopsy slide.
Safety remained close to placebo across the phase 2 cohort
Tolerability will determine whether the drug can compete in a market already dense with biologics, small molecules, and next-generation antibodies. On that front, the early safety profile looks reassuring. Mostly grade 2 or lower adverse events occurred in 36% of patients across the three emvistegrast dose groups, compared with 37% in the placebo arm. Serious adverse events were seen in 2% of emvistegrast recipients, and none were considered related to treatment. Discontinuation because of adverse events was rare, affecting just 1% of all trial participants.
For an oral immunology drug, that balance is encouraging. Ulcerative colitis therapies live or die on the trade-off between efficacy and systemic toxicity, and oral agents are often judged even more harshly because they are expected to be simpler to take without bringing a heavier adverse-event burden. A low discontinuation rate in a randomized placebo-controlled study makes the program easier to justify for late-stage development, even before durability data are available.
Harder-to-treat patients and durability remain the real test
The trial population was not dominated by the most refractory cases. Gilead reported that 78% of participants were either new to advanced therapies or had not previously failed one, while 22% had failed one or two advanced therapies. That mix leaves an important question open: how much of the observed benefit will persist in patients who have already cycled through advanced agents and carry more treatment-resistant disease biology?
Durability is the other unresolved issue. The current readout centers on week 12, which is useful for identifying signal but not enough to establish maintenance of benefit. Ongoing follow-up is expected to clarify whether the gains in response, remission, and mucosal improvement can be sustained over time. In ulcerative colitis, short-term induction success can evaporate if the pathway is not robust enough to keep inflammatory trafficking suppressed through the maintenance phase.
Gilead’s development strategy is already pointed beyond monotherapy. Swati Tole, M.D., senior vice president of clinical development for inflammation, said the company plans to initiate a phase 3 monotherapy study in 2027 and sees emvistegrast as a potential backbone for future combination approaches.
Competitive pressure will rise fast if phase 3 confirms the signal
Emvistegrast is entering a market where mechanism classes are already well established. Takeda’s Entyvio also targets the α4β7 pathway, though it is given intravenously or subcutaneously rather than as an oral daily pill. AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya target IL-23, while AbbVie’s Rinvoq is an oral JAK inhibitor. Merck has also posted positive phase 3 data for the anti-TL1A antibody tulisokibart after its Prometheus Biosciences acquisition.
The competitive pressure is real, but route of administration still shapes patient choice. A once-daily pill can lower the friction of treatment, particularly for people who prefer to avoid infusion centers or injections. If emvistegrast preserves this efficacy pattern in larger trials, the convenience advantage could prove clinically relevant rather than merely cosmetic.
Evercore ISI called the data “the strongest datasets ever for a monotherapy in UC,” and that assessment reflects more than enthusiasm around a single readout. It speaks to the possibility that Gilead has found a differentiated oral asset in a therapeutic area where many programs can improve symptoms but fewer can credibly move remission and mucosal healing together.
The next step is not interpretation. It is confirmation in larger, longer trials that can answer whether the benefit holds in more refractory disease and whether week 12 success translates into durable control.